Participated · Series A · Jan 2025

Nucleus Genomics provides clinical-grade whole-genome sequencing and comprehensive genetic risk assessments covering over 800 diseases. The platform combines genomics with lifestyle and wearable data to contextualize health information and deliver personalised recommendations. The company recently acquired Irish biotech Cambrean, an AI-based health platform that converts Oura ring and Apple Watch data into actionable health insights, and is rolling out features such as AI Doctor, pharmacogenomics, and family forecasting. Nucleus integrates with partners like Bionic Health and Legacy to expand consumer health offerings. Founded in the U.S. in 2021 by Kian Sadegh, the company emphasises making whole-genome sequencing widely accessible to prevent avoidable genetic tragedies. Financially, it has raised venture capital including a $14M Series A and prior investments from Seven Seven Six and Founders Fund. Nucleus Genomics offers a platform that calculates polygenic risk scores by analyzing users' uploaded genetic data from at‑home testing services or data from its own testing kits. The company lets customers order its genetic testing kit or upload results obtained elsewhere and provides information about genetic predisposition to certain conditions. Polygenic risk scores have faced scrutiny for European population bias, and the company says it aims to build models that work across populations. Nucleus emphasizes user data ownership and granular control over how and whether data is shared for research. The company has not yet launched mainstream and it is unclear how broader consumer access will look. Following the recent raise, Nucleus plans to grow its team and establish its own genetic testing infrastructure, including buying testing kits in bulk, and is considering international expansion. Nucleus Genomics provides a consumer-facing platform where users can upload genetic data from services like 23andMe or Ancestry, or order a testing kit, and receive polygenic risk scores via the company’s proprietary algorithms. The product focuses on presenting genetic and non-genetic information in a user-friendly format and aims to eventually calculate absolute disease risk. The company is still developing its polygenic risk score algorithms — described by the founder as the startup’s "secret sauce" — and plans to launch around January 2022. Nucleus says it will also enable users to opt in to share genetic data with drug companies in exchange for a potential dividend payment. The startup plans to grow its team from three to six or seven members as it readies the product. Financially, Nucleus announced a $3.5M seed raise to support algorithm development, product launch, and team expansion.

Participated · Series B · Dec 2024

Sollis Health operates a high-touch medical membership model that provides members unlimited access to ER-trained physicians, onsite advanced imaging, and diagnostic capabilities around the clock. The company markets itself as the first urgent and emergency concierge care provider, eliminating wait times and complexities associated with conventional healthcare. Sollis currently operates centers in New York, the Hamptons, Los Angeles, San Francisco, and South Florida and plans new flagship and clinic openings in Texas, Miami, and Silicon Valley. Since its Series A in 2021 the company says membership has grown more than threefold, and it recently rolled out a nationwide Family membership tier and a Family+ tier in Los Angeles. Proceeds from the recent raise will fund nationwide expansion, product innovation, proprietary technology to enhance the member experience, and scaling of operations to meet growing demand. The company emphasizes 24/7 in-person and telehealth availability as a core differentiator for urgent and emergency issues. Sollis Health operates a membership model offering round-the-clock concierge urgent and emergency care through state-of-the-art medical centers and virtual visits. Its membership includes unlimited in-center and virtual visits, routine labs, wound care, certain procedures, expedited specialist referrals, and optional onsite advanced imaging and house calls. The company has opened flagship centers in Palm Beach and San Francisco and operates sites in New York City, The Hamptons, and Los Angeles. Sollis reports a 100% CAGR in membership since 2019 with annual retention rates approaching 90%. Management plans to use new capital to open five additional centers through 2024 and invest in technological and product enhancements to improve the patient and provider experience. To date the company has raised over $53 million in equity. Sollis Health operates medical concierge practices offering 24/7 urgent care, onsite labs, advanced imaging, virtual visits and in-home services, including monoclonal antibody treatment for Covid-19. Launched in New York in 2019, the company runs clinics in New York, Los Angeles, San Francisco, Miami and Palm Beach and staffs facilities with emergency medicine physicians. Sollis uses an annual membership model priced between $1,000–$5,000 per year that includes unlimited clinic visits and varying tiers by age. Financially, the company has achieved a revenue compound annual growth rate of 150% and maintains a long-run average 90% adjusted renewal rate, currently serving more than 8,000 patients. Sollis plans to grow to more than 12,000 patients within the next year and to expand patient reach in existing and new markets. Through its member-concierge and patient advocacy teams, Sollis secures expedited specialist visits and helps members navigate the broader medical system.